Alan Strunga, M.Sc.
Molecular and Cell Biology and Genetics
Research interestsThrombolysis is a promising treatment that aims to dissolve a blood clot that forms in a blood vessel and causes ischemic diseases such as stroke. The effective and safe administration of thrombolytics depends on a combination of several properties such as fibrin-specificity, activity, stability, and half-life in the bloodstream. So far, fibrin-specific tissue plasminogen activator (rt-PA) is the only agent approved for use in stroke. However, it is far from optimal for the high effectiveness of this treatment. Within this project, the properties and mechanism of action of various thrombolytics (rt-PA, desmoteplases, staphylokinases, urokinases, etc.) will be studied. Based on the obtained mechanistic data, mutant variants with improved properties for clinical use will be designed and constructed. The project will be solved in cooperation with the International Center for Clinical Research of St. Anne’s University Hospital in Brno, the Institute of Biophysics of the Academy of Sciences of the Czech Republic and the biotechnological company Biovendor.
Education2021 Bc., Quality, Reliability & Safety, Faculty of Mechanical Engineering, Brno University of Technology, Brno
2021 Mgr., Analytical Biochemistry, Faculty of Science, Masaryk University, Brno
2018 Bc., Biochemistry, Faculty of Science, Masaryk University, Brno
Research stays2021-22 Heat Transfer and Fluid Flow Laboratory, BUT (Brno, Czech Republic)
2020 Higher Institute of Agronomy, University of Lisbon (Lisbon, Portugal)
2019-20 RECETOX, Masaryk University, (Brno, Czech Republic)
2018 CEITEC, Masaryk University, (Brno, Czech Republic)